Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

BACKGROUND: Tamoxifen, the most frequently used drug for treating estrogen receptor-positive breast cancer, must be converted into active metabolites to exert its therapeutic efficacy, mainly through CYP2D6 enzymes. The objective of this study was to investigate the impact of CYP2D6 polymorphisms on...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Hennig, Ewa E., Piatkowska, Magdalena, Karczmarski, Jakub, Goryca, Krzysztof, Brewczynska, Elzbieta, Jazwiec, Radoslaw, Kluska, Anna, Omiotek, Robert, Paziewska, Agnieszka, Dadlez, Michal, Ostrowski, Jerzy
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4522133/
https://ncbi.nlm.nih.gov/pubmed/26232141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1575-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados